Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective

Journal of Oncology Practice

Volumn 9, Issue 5, 2013, Pages

  Kreys, Eugene D ^a   Koeller, Jim M ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PATHWAY; COLORECTAL CANCER; COST CONTROL; DRUG COST; HEALTH INSURANCE; HEALTH PROGRAM; HOSPITAL COST; HOSPITALIZATION COST; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PROTOCOL COMPLIANCE; RETROSPECTIVE STUDY; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COST SAVINGS; DRUG COSTS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LUNG NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE;

EID: 84892580401     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2012.000871     Document Type: Review

References (39)

1. National Cancer Institute: Cancer trends progress report 2011/2012 update: Costs of cancer care. http://progressreport.cancer.gov/doc-detail.asp? pid- 1&did-2009&chid-95&coid-926&
2. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360: 626-633, 2009
3. Panella M, Marchisio S, Di Stanislao F: Reducing clinical variations with clinical pathways: Do pathways work? Int J Qual Health Care 15: 509-521, 2003 (Pubitemid 37540788)
4. Milliman, Fitch K, Pyenson B: Cancer patients receiving chemotherapy: Opportunities for better management. http://www.publications.milliman.com/ research/health-rr/pdfs/cancer-patients-receiving-chemotherapy.pdf
5. Hofmann PA: Critical path method: An important tool for coordinating clinical care. Jt Comm J Qual Improv 19: 235-246, 1993
6. Meropol NJ, Schulman KA: Cost of cancer care: Issues and implications. J Clin Oncol 25: 180-186, 2007 (Pubitemid 350003031)
7. Kolodziej M, Hoverman JR, Garey JS, et al: Benchmarks for value in cancer care: An analysis of a large commercial population. J Oncol Pract 7: 301-306, 2011
8. Newhouse JP: Medical care costs: How much welfare loss? J Econ Perspect 6: 3-21, 1992
9. Dartmouth Institute for Health Policy and Clinical Practice: Health care spending, quality and outcomes: More isn't always better. http://www. dartmouthatlas. org/downloads/reports/Spending-Brief-022709.pdf
10. Pearson SD, Goulart-Fisher D, Lee TH: Critical pathways as a strategy for improving care: Problems and potential. Ann Intern Med 123: 941-948, 1995
11. de Vries M, van Weert JC, Jansen J, et al: Step by step development of clinical care pathways for older cancer patients: Necessary or desirable? Eur J Cancer 43: 2170-2178, 2007 (Pubitemid 47539126)
12. Rotter T, Kinsman L, James E, et al: Clinical pathways: Effects on professional practice, patient outcomes, length of stay and hospital costs. Cochrane Database Syst Rev 3:CD006632, 2010
13. Will clinical pathways work? Insurers say they are willing to give up control over what they pay for to reduce cancer costs - But oncologists may think differently. Biotechnol Healthc 7: 16-20, 2010
14. Neubauer MA, Hoverman JR, Kolodziej M, et al: Cost effectiveness of evidence- based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract 6: 12-18, 2010
15. Hoverman JR, Cartwright TH, Patt DA, et al: Pathways, outcomes, and costs in colon cancer: Retrospective evaluations in two distinct databases. J Oncol Pract 7:52s-59s, 2011 (suppl)
16. Doloresco F, Fominaya C, Schumock GT, et al: Projecting future drug expenditures: 2011. Am J Health Syst Pharm 68: 921-932, 2011
17. Hoffman JM, Doloresco F, Vermeulen LC, et al: Projecting future drug expenditures: 2010. Am J Health Syst Pharm 67: 919-928, 2010
18. Hoffman JM, Li E, Doloresco F, et al: Projecting future drug expenditures: 2012. Am J Health Syst Pharm 69: 405-421, 2012
19. Hoffman JM, Shah ND, Vermeulen LC, et al: Projecting future drug expenditures: 2009. Am J Health Syst Pharm 66: 237-257, 2009
20. Taylor L: US cancer drug spending will rise 34%-43% by 2013: Study. http://www.pharmatimes.com/Article/11-05-24/US-cancer-drug-spending- will-rise-34-43-by-2013-study.aspx
21. Hillner BE, Smith TJ: Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 27: 2111-2113, 2009
22. Express Scripts: 2009 Drug trend report. http://www.express-scripts.com/ research/research/dtr/archive/2009/
23. Express Scripts: 2010 drug trend report. http://www.express-scripts.com/ research/research/dtr/archive/2010/
24. Elliott R, Payne K: Statistical Handling of Data in Economic Analysis: Essentials of Economic Evaluation in Healthcare. London, United Kingdom, Pharmaceutical Press, 2005, pp 185-202
25. Thomson Reuters: Thomson Reuters healthcare spending index: Costs climb 5.8 percent for employers in 2010. http://thomsonreuters.com/news-ideas/ press-releases/?itemId-434502
26. Health Care Cost Institute: 2010 health care cost and utilization report. http:// www.healthcostinstitute.org/news-and-events/press-release-2010-health- care-costand- utilization-report
27. Martin AB, Lassman D, Washington B, et al: Growth in US health spending remained slow in 2010: Health share of gross domestic product was unchanged from 2009. Health Aff (Millwood) 31: 208-219, 2012
28. Thomson Reuters: Health care costs rise more than 7 percent for U.S. employers in 2009. http://factsforhealthcare.com/management/Assets/ EmployerNormsBook.pdf
29. Thomson Reuters: New Thomson Reuters index reports healthcare inflation for privately insured: Costs climbed 6.3 percent in year ending Q2 2010. http:// www.prnewswire.com/news-releases/new-thomson-reuters-index-reports-health care-inflation-for-privately-insured-costs-climbed-63-percent-in-year-ending-q2- 2010-107185518.html
30. Reference deleted
31. Barber JA, Thompson SG: Analysis and interpretation of cost data in randomised controlled trials: Review of published studies. BMJ 317: 1195-1200, 1998 (Pubitemid 28488509)
32. Haines IE, Olver I: Are guidelines on use of colony-stimulating factors in solid cancers flawed? Intern Med J 39: 259-262, 2009
33. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24: 3187-3205, 2006 (Pubitemid 46638957)
34. Aapro MS, Bohlius J, Cameron DA, et al: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47: 8-32, 2011
35. Timmer-Bonte JN, Adang EM, Smit HJ, et al: Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 24: 2991-2997, 2006 (Pubitemid 46638931)
36. Chouaid C, Bassinet L, Fuhrman C, et al: Routine use of granulocyte colonystimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: An analysis using a Markov model. J Clin Oncol 16: 2700-2707, 1998 (Pubitemid 28363033)
37. Gruschkus SK, Lairson D, Dunn JK, et al: Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy. Value Health 14: 253-262, 2011
38. Aapro M, Molassiotis A, Dicato M, et al: The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER). Ann Oncol 23: 1986-1992, 2012
39. Gilmore JW, Peacock NW, Gu A: Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting (CINV) in U.S. community oncology practice: INSPIRE study. J Clin Oncol 30, 2012 (suppl; abstr 167). http://meetinglibrary.asco.org/content/104059-126